Literature DB >> 12966277

Long-term suppression of infection in total joint arthroplasty.

Nalini Rao1, Lawrence S Crossett, Raj K Sinha, Jack L Le Frock.   

Abstract

Optimal treatment for a chronic infected prosthesis is the removal of infected and necrotic tissue and all the components of the prosthesis with staged revision in conjunction with systemic antibiotics. If this is not possible because of the poor general condition of the patient, because of unacceptable functional results secondary to removal of the prosthesis, or because the patient refuses surgery in an attempt to salvage the infected prosthesis, a reasonable alternative is long-term oral suppressive antibiotic therapy for maintenance of a functioning prosthesis. Prompt recognition with rapid debridement and initiation of antibiotic therapy seems crucial. Our study confirms a favorable outcome of maintenance of functioning prostheses in 86.2% of patients after a mean followup of 5 years. All patients had initial debridement with 4 to 6 weeks of systemic antibiotic therapy. Advanced age did not seem to predict poor outcome. Joint location, duration of symptoms, and the time of onset of infection did not predict success or failure. The overall success rate for Staphylococcus aureus prosthetic joint infection was 69% after a mean followup of 5 years. The ideal regimen and optimal duration of oral suppressive therapy for a favorable outcome is not well-established and needs additional data with prospective multicenter studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12966277     DOI: 10.1097/01.blo.0000087321.60612.cf

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  26 in total

1.  Antimicrobial therapy for bone and joint infections.

Authors:  Saima Aslam; Rabih O Darouiche
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

Review 2.  [Periprosthetic infections of the hip joint : Clinical approach].

Authors:  H M L Mühlhofer; H Gollwitzer; F Lenze; S Feihl; F Pohlig; R von Eisenhart-Rothe; J Schauwecker
Journal:  Orthopade       Date:  2015-05       Impact factor: 1.087

Review 3.  Two-Stage Revision Arthroplasty for the Treatment of Prosthetic Joint Infection.

Authors:  Ryan S Charette; Christopher M Melnic
Journal:  Curr Rev Musculoskelet Med       Date:  2018-09

Review 4.  [Periprosthetic infections in patients with rheumatism : A challenge].

Authors:  J Fussi; C Perka; L Renner
Journal:  Z Rheumatol       Date:  2016-12       Impact factor: 1.372

5.  Two-stage revision surgery for infected total knee replacements: reasonable function and high success rate with the use of primary knee replacement implants as temporary spacers.

Authors:  Ben Arthur Marson; Samuel T Walters; Benjamin V Bloch; Khosrow Sehat
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-08-05

6.  Prolonged suppressive antibiotic therapy is successful in the management of prosthetic joint infection.

Authors:  N A Sandiford; J R Hutt; D O Kendoff; P A Mitchell; M Citak; L Granger
Journal:  Eur J Orthop Surg Traumatol       Date:  2019-10-01

Review 7.  Is prosthesis retention effective for chronic infections in hip arthroplasties? A systematic literature review.

Authors:  M Maillet; P Pavese; D Bruley; A Seigneurin; P François
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-30       Impact factor: 3.267

8.  History of methicillin-resistant Staphylococcus aureus (MRSA) surgical site infection may not be a contraindication to ventral hernia repair with synthetic mesh: a preliminary report.

Authors:  C W Hicks; J A Blatnik; D M Krpata; Y W Novitsky; M J Rosen
Journal:  Hernia       Date:  2013-01-18       Impact factor: 4.739

9.  Prosthetic joint infections.

Authors:  Saima Aslam; Rabih O Darouiche
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

10.  A novel approach for salvaging infected prosthetic mesh after ventral hernia repair.

Authors:  J A Trunzo; J L Ponsky; J Jin; C P Williams; M J Rosen
Journal:  Hernia       Date:  2009-02-12       Impact factor: 4.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.